small molecule

RUBRACA

RUCAPARIB CAMSYLATE

Loss of exclusivityAugust 2035latest FDA-listed patent expiry

CompanyPHARMAAND GMBH

Drug detail

Brand name	RUBRACA
Active ingredient	RUCAPARIB CAMSYLATE
Strength	EQ 300MG BASE
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	December 2016
Marketing status	RX

Listed patents

Patent	Expires	Type
10130636	August 2035	use U-2830
9987285	August 2035	product
8859562	August 2031	use U-2830
9861638	February 2031	use U-2273
8754072	February 2031	substance, product
9045487	February 2031	substance, product
10278974	February 2031	product
8071579	August 2027	use U-2830
8143241	August 2027	use U-2830

Regulatory exclusivity

Code	Expires
I-982	December 2028

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from PHARMAAND GMBH